Volume 1, Issue 8

Button: Follow us on Facebook! Button: Follow us on Twitter!

Announcements
[divider]

Cancer Awareness Month

may-ribbons
March is…
  • Brain Cancer Awareness Month
  • Melanoma and Skin Cancer Awareness Month
[divider]
We Asked a Nurse
ShakiraJordanIn recognition of National Nurses Month, CC:Report is proud to present the first installment of a new regular feature. Every month we will highlight a nurse working at the the GRU Cancer Center, focusing not only the things they do for our patients and their families, but their own interests as well. Read more…
[divider]
Art in Science
cancer-sqrThe GRU Cancer Center is accepting submissions to its Art in Science Collection. Read more…
[divider]

Cancer Campaign Wins Silver

campaign Georgia Regents Health recently won the Silver Astor Award for its Cancer outdoor marketing campaign. Read more…
[divider]
[divider]
Not a week goes by that disparity is not an issue

Director's Corner: Samir N. Khleif, MD
“In health there is freedom. Health is the first of all liberties.” Henri Frederic Amiel

Every year, the issue of cancer disparity is addressed during National Minority Cancer Week. Established in 1987 with a U.S. House of Representatives House Resolution, the week was set aside to recognize and address cancer’s “…disproportionately severe impact on minorities and the economically disadvantaged.”

And so, for one week, it is addressed in the media. There are websites and fundraisers. The stats are rolled out and examined.

And then, quite often, people move on to the next thing.

At the GRU Cancer Center, we don’t have a National Minority Cancer Week.

We have 52 of them.

This issue, both locally and nationally, is so vitally important that addressing it needs to be a full-time job. It’s not something that can be fixed in a week. It’s something that requires constant and consistent focus. While we should all appreciate the attention something like National Minority Cancer Week brings to significant issues, it’s also important that our work on decoding disparity issues continues year around.

Have you Heard…?

  • New Intramural Award Opportunity
    The Cancer Centers from Georgia Regents University and the University of Georgia hosted a retreat on November 1, 2013 focused on Cancer Biomarkers and Therapeutics.A main objective of this retreat was to develop complementary and synergistic cancer research within the Cancer Biomarker and Therapeutics theme through collaborative projects between members of the two University System of Georgia institutions.  >> Continue reading
  • Relay Recap
    On May 2, the GRU Cancer Center participated as a presenting sponsor in the American Cancer Society’s Augusta Relay for Life at Westside High School. >> Continue reading
  • NIH Policy Change for R01 Resubmissions
    The National Institutes of Health (NIH) … announces a change in policy on application submissions. Effective immediately, for application due dates after April 16, 2014, following an unsuccessful resubmission (A1) application, applicants may submit the same idea as a new (A0) application for the next appropriate due date… >> Continue reading
  • Employee Picnic
    In appreciation for the extraordinary work of everyone here, the GRU Cancer Center will be hosting an employee picnic June 5th outside on the lawn of the Research building (CN).  >> Continue reading

 

Featured Research
  • Deciphering breast cancer metastasis
    Researchers at the GRU Cancer Center have identified new molecular players and potential biomarkers in breast cancer tumorigenesis.  A process known as epithelial-to-mesenchymal transition (EMT) represents changes in cancer cell characteristics that accompany metastatic progression.  Epithelial-like cancer cells express different molecular constituents than do mesenchymal-like cells. >> Continue reading

 

Grants News

  • John K. Cowell, PhD, received a 5-year, $1.4M R01 grant from NIH/NCI for “Genetic analysis of myeloproliferative disease.”The major goals of this project are to (1) define the genetic changes associated with acute myeloid leukemia (AML) development associated with myeloproliferative disease, (2) determine why the BCR-FGFR1 fusion gene produces a more aggressive incurable disease, and (3) use a proteomics approach to define targets of the fusion kinases in the development of AML.

 

Newly Activated Clinical Trials

  • Daron Ferris, MD, received $141K from Merck Sharp & Dohme Corp./Merck for “A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Preadolescents and Adolescents (9 to 14 year olds) with a Comparison to Young Women (16 to 26 year olds).”
  • Jeremy Pantin, MD, received $186K from Esanex, Inc., for “A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 in Subjects with Refractory Hematological Malignancies.”

 

Recent Publications

About Jagwire

Jagwire is the official source for news and stories from Augusta University and AU Health. Daily updates highlight the many ways students, faculty, staff, researchers and clinicians "bring their A games" in classrooms and clinics on four campuses in Augusta and locations across the state of Georgia. Read on for stories of innovation in education and health care, opportunities at the center of Georgia’s new cybersecurity hub, and experiential learning that blends arts and application, humanities and the health sciences. Have a story to share with Jaguar Nation? Contact the Division of Communications & Marketing.